Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may provide a promising development for obesity loss . Early patient trials have indicated considerable reductions in visceral tissue, conceivably outperforming current weight-loss treatments. However , further stu